Introduction of typhoid vaccine in the expanded immunization program of Pakistan [PDF]
Human Vaccines & Immunotherapeutics, 2021 Worldwide, typhoid infects 11–20 million people each year. In Pakistan, the first extensively drug-resistant (XDR) typhoid was reported in 2016 resulting in an epidemic.
Fahmida Aslam, Yang Yue, Majid Aziz
doaj +3 more sources
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator [PDF]
Human Vaccines & Immunotherapeutics, 2022 The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection.
Subhash Thuluva +4 more
doaj +3 more sources
Typhoid conjugate vaccine implementation in India: A review of supportive evidence
Vaccine: XBackground: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and
Bhim Gopal Dhoubhadel
exaly +4 more sources
Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. [PDF]
Clin Infect Dis, 2020 Control of Salmonella enterica serovar typhi (S. typhi), the agent of typhoid fever, continues to be a challenge in many low- and middle-income countries. The major transmission route of S.
Syed KA +10 more
europepmc +2 more sources
Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial. [PDF]
Int Health, 2020 Background In a cluster randomized trial (CRT) of a Vi polysaccharide vaccine against typhoid in the slums of Kolkata we found evidence of vaccine herd protection.
Ali M +14 more
europepmc +2 more sources
EClinicalMedicine, 2023 Background A cluster-randomised trial of Vi-tetanus toxoid (Vi-TT) conjugate vaccine conducted in urban Bangladeshi children found a high level of direct protection by Vi-TT but no significant vaccine herd protection.
Farhana Khanam +2 more
exaly +2 more sources
Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal. [PDF]
Clin Infect Dis, 2019 Typhoid fever is estimated to affect over 20 million people per year worldwide, with infants, children, and adolescents in south-central and southeast Asia experiencing the greatest burden of disease.
Colin-Jones R +16 more
europepmc +2 more sources
Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. [PDF]
Clin Infect Dis, 2019 Typhoid fever has had a major impact on human populations, with the causative pathogen Salmonella enterica serovar Typhi implicated in many outbreaks through history.
Meiring JE +4 more
europepmc +2 more sources
Lancet, The, 2021 Summary Background Typhoid fever remains a major cause of morbidity and mortality in low-income and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended by WHO for implementation in high-burden countries, but there is ...
Firdausi Qadri +2 more
exaly +2 more sources
Vaccine: X, 2022 Introduction: Typhoid fever is a public-health problem in Harare, the capital city of Zimbabwe, with seasonal outbreaks occurring annually since 2010.
M. Poncin +24 more
doaj +2 more sources